

Points to make

1. Efficiency savings of around £10m may be possible but these are based on inadequate costs. A priority is to improve management information.
2. Whilst a SHA is ruled out for now, this remains an option should RHAs fail to co-operate with the new arrangements and surrender some autonomy.
3. We have opted for a National Director drawn from the ranks of the Regional Transfusion Directors. This is needed to make the package sellable to these and to the Royal College of Pathologists and JCC. The task is however management rather than medical and a non-medical Director sometime in the future remains an option.
4. Cross charging will help Regions to help each other without loss, and for Regions to supply CBLA without loss, and for CBLA to be funded without top slicing the RHAs as at present.